Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12039773 | 0.92 | LMNA (0.46) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL15160766 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL15160693 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL9936087 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL25110753 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL23710842 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL21106768 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL22861696 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL21401388 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 | |
| SCHEMBL13884328 | 0.89 | LMNA (0.43) | LMNACACNA2D1HRH4HRH3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240226226-A1 | KAPPA-OPIOID RECEPTOR AGONIST IMPLANTS FOR TREATMENT OF PRURITUS | TITAN PHARMACEUTICALS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226226-A1 | KAPPA-OPIOID RECEPTOR AGONIST IMPLANTS FOR TREATMENT OF PRURITUS | TITAN PHARMACEUTICALS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11814372-B2 | Agonists of EPHA and their uses | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
| US-7884099-B2 | such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections | CUMBRE IP VENTURES, L.P. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-7481993-B2 | Chelators for radioactively labeled conjugates comprising a stabilizing sidechain | SCHERING AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-6919291-B2 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040110631-A1 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-06-10 | — | — | US | disclosed |
| EP-1349653-A2 | FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002036639-A2 | FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | LMNA 1621/4885CACNA2D1 2540/4885HRH4 4137/4885 |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | LMNA 97/4885CACNA2D1 748/4885HRH4 2547/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | LMNA 2444/4885CACNA2D1 2502/4885HRH4 4071/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | LMNA 2494/4885CACNA2D1 3803/4885HRH4 291/4885 |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | LMNA 1909/4885CACNA2D1 4312/4885HRH4 3762/4885 |
| US-20240226226-A1 | KAPPA-OPIOID RECEPTOR AGONIST IMPLANTS FOR TREATMENT OF PRURITUS | OPRK1, OPRL1, OPRD1 | LMNA 4772/4885CACNA2D1 2038/4885HRH4 71/4885 |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | LMNA 2182/4885CACNA2D1 713/4885HRH4 2566/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | LMNA 402/4885CACNA2D1 4473/4885HRH4 1681/4885 |
| US-20040110631-A1 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | FZD7, FOS, COG4 | LMNA 2335/4885CACNA2D1 1464/4885HRH4 2095/4885 |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | GPR119, FFAR3, FFAR2 | LMNA 3596/4885CACNA2D1 1228/4885HRH4 309/4885 |
| US-11814372-B2 | Agonists of EPHA and their uses | EPHA2, EPHA7, EPHA1 | LMNA 2464/4885CACNA2D1 3329/4885HRH4 1846/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | LMNA 3292/4885CACNA2D1 2999/4885HRH4 252/4885 |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | LMNA 1918/4885CACNA2D1 4875/4885HRH4 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.